Table 1.
Treatment received by advanced stage HCC patients (BCLC stage C and D) grouped by stage and hospice status#. (n = 397)
| Stage C | Stage D | ||||
|---|---|---|---|---|---|
| Non-Hospice User n = 108 (%) |
Hospice User n = 209 (%) |
Non-Hospice User n = 24 (%) |
Hospice User n = 56 (%) |
Total n = 397 (%) |
|
| Curative intent | |||||
| Transplant | 8 (7.4) | 1 (0.5) | 9 (37.5) | 4 (7.1) | 22 (5.5) |
| Surgery | 11 (10.2) | 11 (5.3) | 1 (4.2) | 0 (0) | 23 (5.8) |
| Ablation* | 26 (24.1) | 14 (12.0) | 5 (20.8) | 8 (14.3) | 53 (13.4) |
| Non-curative intent | |||||
| Liver directed** | 60 (55.6) | 98 (46.9) | 11 (45.8) | 28 (50.0) | 197 (49.6) |
| Systemic - Sorafenib | 33 (30.6) | 121 (57.9) | 3 (12.5) | 27 (48.2) | 184 (46.3) |
| Systemic - others*** | 10 (9.3) | 27 (13.0) | 3 (12.5) | 2 (3.6) | 42 (10.6) |
#
Patient may have received more than one treatment category; therefore, the total treatment count may exceed the cohort number.
*
Ablation: Radiofrequency ablation, Ethanol ablation, Microwave ablation
**
Liver directed therapy: Transarterial Embolization or Chemoembolization, Y-90, Radioembolization, Radioimmunotherapy, Cryotherapy
***
Systemic chemotherapy - others: Dexorubicin (Doxil, Adriamycin), Bevacizumab (Avastin), Capecitabine (Xeolda), Gemitabine (Gemzar), Other Chemo Agent, and Clinical Trials